Diagnostic tests for Cushing’s syndrome differ from published guidelines: data from ERCUSYN

Elena Valassi1, Holger Franz2, Thierry Brue3, Richard A Feelders4, Romana Netae-Maier5, Stylianos Tsagarakis6, Susan M Webb1, Maria Yaneva7, Martin Reincke8, Michael Droste9, Irina Komerdus10, Dominique Maiter11, Darko Kastelan12, Philippe Chanson13,14,15, Marija Pfeifer16, Christian J Strasburger17, Miklós Tóth18, Olivier Chabre19, Antoine Tabarin20, Michal Krsek21, Carmen Fajardo22, Marek Bolanowski23, Alicia Santos1, John A H Wass24 and Peter J Trainer25, for the ERCUSYN Study Group1

11IB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain, 2Lohmann & Birkner Health Care Consulting GmbH, Berlin, Germany, 3Aix-Marseille Université, CNRS, CRN2M UMR 7286, and APHM, Hôpital Conception, Marseille, France, 4Erasmus University Medical Centre, Rotterdam, The Netherlands, 5Radboud University Medical Centre, Nijmegen, The Netherlands, 6Athens Polyclinic General Hospital, Evangelismos Hospital, Athens, Greece, 7Medical University of Sofia, Sofia, Bulgaria, 8Medizinische Klinik und Poliklinik IV, Campus Innestadt, Klinikum der Universität München, München, Germany, 9Praxis für Endokrinologie Droste, Oldenburg, Germany, 10Moscow Regional Research Clinical Institute, Moscow, Russia, 11UCL Cliniques Universitaires St Luc, Brussels, Belgium, 12Department of Endocrinology, University Hospital Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia, 13Univ Paris-Sud, Université Paris-Saclay UMR-S1185, Le Kremlin Bicêtre, Paris, France, 14Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service de Endocrinologie et des Maladies de la Reproduction, Le Kremlin Bicêtre, Paris, France, 15Institut National de la Santé et de la Recherche Médicale U1185, Le Kremlin Bicêtre, Paris, France, 16Department of Endocrinology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 17Division of Clinical Endocrinology, Department of Medicine CCM, Charité-Universitätsmedizin, Berlin, Germany, 182nd Department of Medicine, Semmelweis University, Budapest, Hungary, 19Service d'Endocrinologie-Diabétologie-Nutrition, Grenoble Cedex, France, 20Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France, 212nd Department of Internal Medicine, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic, 22Department of Endocrinology, Hospital Universitario de la Ribera, Alzira, Spain, 23Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University, Wroclaw, Poland, 24Oxford Radcliffe Hospitals NHS Trust, Oxford, UK, and 25Department of Endocrinology, Christie Hospital, Manchester, UK

(1Details of the ERCUSYN Study Group is presented in Acknowledgements section)

Abstract

Objective: To evaluate which tests are performed to diagnose hypercortisolism in patients included in the European Registry on Cushing’s syndrome (ERCUSYN), and to examine if their use differs from the current guidelines.

Patients and methods: We analyzed data on the diagnostic tests performed in 1341 patients with Cushing’s syndrome (CS) who have been entered into the ERCUSYN database between January 1, 2000 and January 31, 2016 from 57 centers in 26 European countries. Sixty-seven percent had pituitary-dependent CS (PIT-CS), 24% had adrenal-dependent CS (ADR-CS), 6% had CS from an ectopic source (ECT-CS) and 3% were classified as having CS from other causes (OTH-CS).

Results: Of the first-line tests, urinary free cortisol (UFC) test was performed in 78% of patients, overnight 1 mg dexamethasone suppression test (DST) in 60% and late-night salivary cortisol (LSeC) in 25%. Use of LSeC increased in the last five years as compared with previous years (<0.01). Use of HDDST was slightly more frequent in the last 5 years as compared with previous years (<0.05). Of the additional tests, late-night serum cortisol (LSaC) was measured in 62% and 48-h 2 mg/day low-dose dexamethasone suppression test (LDDST) in 33% of cases. ACTH was performed in 78% of patients. LSeC and overnight 1 mg DST supported the diagnosis of both PIT-CS and ADR-CS more frequently than UFC (<0.05).
Conclusions: Use of diagnostic tests for CS varies across Europe and partly differs from the currently available guidelines. It would seem pertinent that a European consensus be established to determine the best diagnostic approach to CS, taking into account specific inter-country differences with regard to the availability of diagnostic tools.

Introduction

Diagnosis of Cushing’s syndrome (CS) is a major clinical issue, due to the rarity of this condition and its variable clinical presentation (1). Several biochemical tests have been proposed for the evaluation of suspected hypercortisolism (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12), but their diagnostic accuracy depends upon etiology of CS, patient’s comorbidities, robustness of the assays, concomitant medications and the setting of investigations (13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23).

According to the most recent clinical practice guidelines (24) developed under the auspice of the Endocrine Society in 2008, initial work-up in patients suspected of having CS should rely on one test with high sensitivity, such as urinary free cortisol (UFC); late-night salivary cortisol (LSaC); overnight 1 mg dexamethasone suppression test (DST) or, in some selected subjects, 48-h 2 mg/day low-dose dexamethasone suppression test (LDDST). In case of abnormal results, patients should undergo a second test, either one of the above or, in some cases, a late-night serum cortisol (LSeC) or a dexamethasone-suppressed CRH stimulation (Dex-CRH) test (24). However it is still not known to which extent these recommendations are followed and/or shared on a large-scale by specialists dealing with patients suspected to have endogenous hypercortisolism.

The European Registry on Cushing’s syndrome (ERCUSYN) is the largest prospective database existing to date which collects information on diagnosis, management and long-term follow-up in CS (25). Because ERCUSYN includes data from 57 centers in 26 European countries, it reflects the ‘real-life’ clinical practice and shows which tests are more frequently used to identify CS throughout Europe.

Thus, the aim of this study was to evaluate how CS is diagnosed in Europe and examine if their use differs from the current guidelines. In addition, we have compared the diagnostic strategies used to identify the different etiologic groups of CS.

Patients and methods

Description of the database

ERCUSYN is a web-based, multicenter, observational study that enrolled 1386 patients from 57 centers in 26 European countries diagnosed between January 1, 2000 and January 31, 2016. Forty-five patients were excluded due to lack of a definitive diagnosis, so 1341 patients were finally analyzed. One-thousand and fourteen patients were prospectively included since October 1, 2008 (when the database was opened), and 327 patients diagnosed since January 1, 2000 were retrospectively entered with yearly updates. Patients were classified into four major etiologic groups: pituitary-dependent CS (PIT-CS), adrenal-dependent CS (ADR-CS; adrenal adenoma), CS from an ectopic source (ECT-CS) and CS from other etiologies (OTH-CS) (Fig. 1).

Etiologic classification was based on histologic documentation of ACTH-secreting or adrenal tumor. In case histological reports were not available, biochemical and clinical resolution of hypercortisolism after surgical resection were used as a diagnostic confirmation. In patients with ECT-CS or OTH-CS who were not operated on, diagnosis was based on biochemical test results and/or imaging, as confirmed by the managing physician.

A detailed description of the database layout has been previously reported (25). This study was aimed at analyzing and evaluating data entered in the ‘diagnosis’ section.

The ‘diagnosis’ section contains information at diagnosis: baseline demographic and anthropometric characteristics, etiology of CS and diagnosis date, delay between onset of symptoms and final diagnosis of CS, other specialists consulted for Cushings symptoms before correct diagnosis, clinical features, comorbidities, bone status and two questionnaires on quality of life (CushingQoL and EuroQoL-5D). It also contains a subsection comprising the following diagnostic tests: urinary free cortisol (UFC), morning serum cortisol (MSeC), late-night salivary cortisol...
ERCUSYN patients included

<table>
<thead>
<tr>
<th>Group</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIT-CS</td>
<td>904 (n = 904)</td>
</tr>
<tr>
<td>ADR-CS</td>
<td>335 (n = 335)</td>
</tr>
<tr>
<td>ECT-CS</td>
<td>80 (n = 80)</td>
</tr>
<tr>
<td>OTH-CS</td>
<td>22 (n = 22)</td>
</tr>
</tbody>
</table>

- **PIT-CS (n = 904)**
  - 440 microadenoma
  - 94 intrasellar macroadenoma
  - 94 extrasellar macroadenoma
  - 181 not seen on MRI
  - 95 not available

- **ADR-CS (n = 335)**
  - 10 bronchial carcinoid
  - 5 small-cell lung carcinoma
  - 2 pancreatic neurenoendoctrine tumor
  - 1 multifocal neurenoendoctrine tumor
  - 1 prostatic carcinoma
  - 1 atypical carcinoid of the mediastinum
  - 1 atypical carcinoid of left basal lung
  - 1 pleural metastasis
  - 1 parotid gland cystoma
  - 2 thymic carcinoma
  - 1 thymic mass (on CT)
  - 1 lung nodule (on CT)
  - 1 neuroendocrine tumor
  - 1 paracardial lesion (on PET)
  - 1 thyroid nodule (on CT, PET, Octreo-Scan)
  - 41 unspecified source

- **ECT-CS (n = 80)**
  - 1 cyclamed CS
  - 1 foci-dependent CS
  - 20 unspecified diagnosis

- **OTH-CS (n = 22)**
  - 1 pituitary adenoma
  - 1 ACTH-dependent adrenal adenoma
  - 2 ACTH-independent adrenal adenoma
  - 1 ACTH-independent adrenal adenoma
  - 2 ACTH-independent adrenal adenoma

Figure 1
Total number of ERCUSYN patients analyzed, divided by etiologic group. CS, Cushing’s syndrome; PIT-CS, pituitary-dependent Cushing’s syndrome; ADR-CS, adrenal-dependent Cushing’s syndrome; ECT-CS, ectopic Cushing’s syndrome; OTH-CS, Cushing’s syndrome from other causes. ADR-CS includes 6 adrenal hyperplasia, 6 primary pigmented nodular adrenocortical disease (PPNAD) and 3 ACTH-independent macronodular adrenocortical hyperplasia (AIMAH).

Statistical analysis
SPSS for Windows version 22.0 (SPSS) was used to perform data analysis. Data on age, BMI and delay to diagnosis are expressed as median (interquartile range (IQR)).

Statistical comparisons were carried out using Mann–Whitney’s U test for quantitative variables and the $\chi^2$ test for categorical variables. Comparisons between the etiologic groups were performed by ANOVA followed by Bonferroni test as a post hoc test or a Kruskal–Wallis $H$ test, depending on the data distribution. To evaluate if the use of a given diagnostic test changed over time, an arbitrary cut-point of 5 years was established and the number of tests in the last 5 years of the ERCUSYN (2010–2015) was compared with the number of tests prior to 2010 (2000–2009). The diagnostic performance of tests within each etiologic group was performed using the McNemar test. The diagnostic performance of tests was compared between the etiologic groups calculating the likelihood ratio from contingency tables; significance was identified using the adjusted residual. Statistical significance was defined as a two-tailed $P$ value ≤0.05.

Results
General characteristics
Of the 1341 patients, 904 (67%) had PIT-CS, 335 (25%) had ADR-CS and 80 (6%) had ECT-CS. Twenty-two (2%) were classified as having OTH-CS (Fig. 1).

The characteristics of the population and the putative delay to diagnosis for each etiologic group are shown in Table 1.
General characteristics of 1341 CS patients included in the ERCUSYN.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>PIT-CS</th>
<th>ADR-CS</th>
<th>ECT-CS</th>
<th>OTH-CS</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>904 (67)</td>
<td>335 (25)</td>
<td>80 (6)</td>
<td>22 (2)</td>
<td>1341</td>
</tr>
<tr>
<td>Gender (F/M)</td>
<td>721/183</td>
<td>283/52</td>
<td>33/80</td>
<td>18/4</td>
<td>1055/286</td>
</tr>
<tr>
<td>% Males</td>
<td>20</td>
<td>16</td>
<td>59 *</td>
<td>18</td>
<td>21</td>
</tr>
<tr>
<td>Age at diagnosis (year) *</td>
<td>43 (20)*</td>
<td>46 (22)</td>
<td>49 (24)</td>
<td>45 (30)</td>
<td>44 (21)</td>
</tr>
<tr>
<td>BMI (kg/m 2)</td>
<td>28 (9)</td>
<td>29 (8)</td>
<td>26 (8)**</td>
<td>29 (10)</td>
<td>28 (9)</td>
</tr>
<tr>
<td>Delay to diagnosis (year) *</td>
<td>2 (3)</td>
<td>2 (2)</td>
<td>1 (1.5)</td>
<td>1 (3)</td>
<td>2 (3)</td>
</tr>
</tbody>
</table>

*Values are presented as median (IQR); *PIT-CS patients were younger at diagnosis vs both ADR-CS and ECT-CS (P < 0.01); **ECT-CS had lower BMI vs the other groups (P < 0.01); *proportion of males was higher in ECT-CS vs PIT-CS and ADR-CS (P < 0.05).

Specific country characteristics

A total of 26 European countries participated in the ERCUSYN (Supplementary Table 1, see section on supplementary data given at the end of this article). Four countries provided more than half of the patients of the database (France (n=247; 18%), the Netherlands (n=198; 15%), Germany (13%; n=174) and Bulgaria (n=88; 7%).

Biochemical assessment

Among the first-line diagnostic tests, UFC was performed across Europe in 78% of patients, overnight 1 mg DST in 60% and LSeC in 20%. The LSeC measurement was used in the diagnostic work-up of 62% of patients. LDDST was used in 33% of cases (Table 2 and Supplementary Table 1). ACTH assessment was performed in 78% of patients. MSeC was reported in 82% of patients.

When countries contributing with at least 20 patients were considered, the use of UFC ranged from 13 to 99%, LSeC from 15 to 96%, overnight 1 mg DST from to 12 to 90% and LSeC from to 0 to 46%. The use of LDDST ranged from 3 to 81% and that of ACTH from 43 to 98%. Dex-CRH test was used in one PIT-CS patient only. Both LSeC and LSeC were more frequently measured in those centers entering more than 20 patients (306/335 (91%) for LSeC and 738/829 (89%) for LSeC) as compared with those entering less than 20 patients (29/335 (9%) for LSeC and 91/829 (11%) for LSeC) in the ERCUSYN (P < 0.01 for both comparisons).

Use of tests over the time

The use of LSeC measurement was more frequent in those patients seen in the last 5 years (2010–2015) (194/629 (31%)) as compared with those seen in the previous years (2000–2010) (141/712 (20%)) (P < 0.01) (Fig. 2A). The use of HDDST was slightly more frequent in the last 5 years as compared with the previous years (192/399 (48%) vs 207/399 (52%); P=0.018) (Fig. 2B). The use of CRH test was less frequent in the last 5 years as compared with the previous years (155/372 (42%) vs 217/372 (58%); P=0.017) (Fig. 2C).

Comparison of tests supporting the diagnosis of CS within each etiologic group

The diagnostic performance of tests within each etiologic group is shown in Fig. 3.

In PIT-CS, LSeC (538/544 (99%)) supported the diagnosis more frequently than both UFC (670/705 (95%)) and LSeC (183/205 (89%)); P < 0.01 for both comparisons. Overnight 1 mg DST (520/531 (98%)) supported the
Biochemical tests used for the differential diagnosis of CS

The diagnostic performance of the tests used to differentiate the etiologies of CS is shown in Table 3.

Measurement of cortisol post-HDDST was used in 30% of patients overall, 79% of whom were PIT-CS and 7% ECT-CS. Assessment of peak post-CRH cortisol was used in 28% of patients, of whom 83% were PIT-CS and 5% ECT-CS. In those patients with negative pituitary MRI, HDDST supported the diagnosis of PIT-CS and ECT-CS in 90 and 88% of cases respectively ($P=0.54$). The CRH test supported the diagnosis of PIT-CS and ECT-CS in 89 and 85% of cases ($P=0.57$) (Table 4).

Of patients with negative IPSS, HDDST supported the diagnosis of PIT-CS and ECT-CS in 100 and 82% respectively ($P=0.15$). The CRH test was diagnostic in the only PIT-CS patient with negative IPSS (100%) and in 75% of ECT-CS ($P=0.43$) (Table 4).

Pituitary imaging for the differential diagnosis of CS

Pituitary MRI was performed in 928 patients (69%), of whom 823 (89%) had PIT-CS, 41 (4%) had ADR-CS, 54 (6%) had ECT-CS and 27 (1%) had OTH-CS. As expected, PIT-CS patients (823/904 (91%)) underwent a pituitary MRI more frequently than the other groups (41/320 (13%) for ADR-CS, 54/80 (68%) for ECT-CS and 10/37 (27%) for OTH-CS; ($P<0.001$)). Pituitary MRI identified an adenoma in 628 of 809 (78%) patients with PIT-CS having results available (440 microadenomas, 94 intrasellar macroadenomas and 94 macroadenomas with extrasellar extension) (Fig. 1). However an image indicating or suggesting a pituitary lesion compatible with a microadenoma was also documented in 10 of 37 (27%) ADR-CS patients, 6 of 53 (11%) ECT-CS patients and 4 of 9 (44%) OTH-CS (Table 3). An intrasellar macroadenoma was observed in one ADR-CS patient (3%). Of the 259 patients with a negative pituitary MRI, 181 (70%) were subsequently diagnosed as having a PIT-CS, 26 ADR-CS (10%), 47 ECT-CS (18%) and 5 OTH-CS (2%).

IPSS was performed in 310 patients overall, of whom 264 (85%) were in the PIT-CS and 28 (9%) in the ECT-CS groups. IPSS confirmed a pituitary source in 254 PIT-CS patients (96%), whereas it did not support a pituitary origin of ACTH hypersecretion in 26 ECT-CS patients (93%) (Table 3).

Of the 181 PIT-CS patients with a negative MRI, 129 (71%) underwent IPSS; in 123 of them (95%), the results
Diagnostic tests in Cushing’s syndrome

Clinical Study  
E Valassi and others

were consistent with a pituitary source of ACTH secretion (Table 5). Inversely, IPSS indicated an extrapituitary source of ACTH in 22 of 23 (96%) ECT-CS patients with a negative pituitary MRI.

Twenty-one PIT-CS patients also underwent pituitary CT, which was negative in 7 (33%) of them. In three of these 7 (43%) patients with negative CT, concomitant MRI documented a microadenoma.

Table 3 Performance of tests used for the differential diagnosis of CS. Numbers refer to tests with available results. Percentages are expressed in parentheses.

<table>
<thead>
<tr>
<th>Differential diagnosis of PIT-CS vs ADR-CS</th>
<th>PIT-CS</th>
<th>ADR-CS</th>
<th>ECT-CS</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTH</td>
<td>640/664 (96)</td>
<td>223/225 (99)</td>
<td>–</td>
</tr>
<tr>
<td>Positive pituitary MRI</td>
<td>628/809 (78)*</td>
<td>10/37 (27)</td>
<td>–</td>
</tr>
<tr>
<td>Positive adrenal imaging*</td>
<td>47/267 (18)</td>
<td>41/298 (14)</td>
<td>–</td>
</tr>
<tr>
<td>Hyperplasia</td>
<td>12/267 (7)</td>
<td>196/298 (66)$</td>
<td>–</td>
</tr>
<tr>
<td>Multiple adenomas</td>
<td>6/267 (2)</td>
<td>22/298 (7)</td>
<td>–</td>
</tr>
<tr>
<td>Differential diagnosis of PIT-CS vs ECT-CS</td>
<td>628/809 (78)**</td>
<td>–</td>
<td>6/53 (11)</td>
</tr>
<tr>
<td>Positive pituitary MRI</td>
<td>273/302 (90)</td>
<td>–</td>
<td>27/29 (93)</td>
</tr>
<tr>
<td>HDDST ACTH</td>
<td>110/120 (92)</td>
<td>–</td>
<td>14/15 (93)</td>
</tr>
<tr>
<td>HDDST UFC</td>
<td>136/145 (94)</td>
<td>–</td>
<td>14/16 (93)</td>
</tr>
<tr>
<td>CRH test cortisol (peak)</td>
<td>269/309 (85)</td>
<td>–</td>
<td>16/19 (84)</td>
</tr>
<tr>
<td>CRH test ACTH (peak)</td>
<td>299/332 (90)</td>
<td>–</td>
<td>16/19 (84)</td>
</tr>
<tr>
<td>Positive IPSS</td>
<td>254/264 (96)**</td>
<td>–</td>
<td>2/28 (7)</td>
</tr>
<tr>
<td>Differential diagnosis of ADR-CS vs ECT-CS</td>
<td>–</td>
<td>223/225 (99)</td>
<td>54/58 (93)</td>
</tr>
<tr>
<td>ACTH</td>
<td>–</td>
<td>223/225 (99)</td>
<td>54/58 (93)</td>
</tr>
<tr>
<td>Positive adrenal imaging*</td>
<td>–</td>
<td>–</td>
<td>20/34 (59)$</td>
</tr>
<tr>
<td>Hyperplasia</td>
<td>–</td>
<td>41/298 (14)</td>
<td>20/34 (59)$</td>
</tr>
<tr>
<td>Single adenoma</td>
<td>–</td>
<td>196/298 (66)**</td>
<td>3/34 (9)</td>
</tr>
<tr>
<td>Multiple adenomas</td>
<td>–</td>
<td>22/298 (7)</td>
<td>2/34 (6)</td>
</tr>
</tbody>
</table>

*It includes evidence of adrenal hyperplasia (uni- or bilateral), uni- or bilateral single adenoma(s) or multiple adenomas (uni- or bilateral) on adrenal ultrasounds (n=84 in PIT-CS; n=122 in ADR-CS; n=10 in ECT-CS); CT (n=190 in PIT-CS; n=250 in ADR-CS; n=27 in ECT-CS) or RMN (n=33 in PIT-CS; n=63 in ADR-CS; n=8 in ECT-CS); $P<0.001 vs PIT-CS; $P<0.01 vs ADR-CS; **P<0.01 vs CT-CS.

Adrenal imaging for the differential diagnosis of CS

Normal adrenal glands were more frequently observed in PIT-CS (171/267 (64%)) as compared with ADR-CS (107/298 (36%)); P<0.01. A single adenoma (uni- or bilateral) was more frequently reported in ADR-CS (196/298 (66%)) than in PIT-CS (19/267 (87%)); P<0.001 (Table 3). Adrenal hyperplasia (uni- or bilateral) was more
Table 4  Percent of high-dose dexamethasone suppression test (HDDST) or corticotropin-releasing hormone test (CRH) supporting the diagnosis of either PIT-CS or ECT-CS. The data are classified based on findings on either pituitary magnetic resonance (MRI) or bilateral inferior petrosal sinus sampling (IPSS).

<table>
<thead>
<tr>
<th>Etiologic group</th>
<th>Cortisol post-HDDST supporting the diagnosis</th>
<th>Cortisol post-CRH supporting the diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>90 (90)</td>
<td>87 (87)</td>
</tr>
<tr>
<td>PIT-CS (%)</td>
<td>90 (90)</td>
<td>87 (87)</td>
</tr>
<tr>
<td>ECT-CS (%)</td>
<td>93 (93)</td>
<td>84 (84)</td>
</tr>
<tr>
<td>P value</td>
<td>0.40</td>
<td>0.12</td>
</tr>
<tr>
<td>Patients with negative pituitary MRI</td>
<td>90 (90)</td>
<td>89 (89)</td>
</tr>
<tr>
<td>PIT-CS (%)</td>
<td>90 (90)</td>
<td>89 (89)</td>
</tr>
<tr>
<td>ECT-CS (%)</td>
<td>88 (88)</td>
<td>85 (85)</td>
</tr>
<tr>
<td>P value</td>
<td>0.54</td>
<td>0.57</td>
</tr>
<tr>
<td>Patients with positive pituitary MRI</td>
<td>89 (89)</td>
<td>88 (88)</td>
</tr>
<tr>
<td>PIT-CS (%)</td>
<td>89 (89)</td>
<td>88 (88)</td>
</tr>
<tr>
<td>ECT-CS (%)</td>
<td>100 (100)</td>
<td>100 (100)</td>
</tr>
<tr>
<td>P value</td>
<td>0.27</td>
<td>0.17</td>
</tr>
<tr>
<td>Patients with IPSS not supporting the pituitary origin</td>
<td>82 (82)</td>
<td>75 (75)</td>
</tr>
<tr>
<td>PIT-CS (%)</td>
<td>82 (82)</td>
<td>75 (75)</td>
</tr>
<tr>
<td>ECT-CS (%)</td>
<td>100 (100)</td>
<td>100 (100)</td>
</tr>
<tr>
<td>P value</td>
<td>0.15</td>
<td>0.43</td>
</tr>
<tr>
<td>Patients with IPSS supporting the pituitary origin</td>
<td>87 (87)</td>
<td>78 (78)</td>
</tr>
<tr>
<td>PIT-CS (%)</td>
<td>87 (87)</td>
<td>78 (78)</td>
</tr>
<tr>
<td>ECT-CS (%)</td>
<td>100 (100)</td>
<td>–</td>
</tr>
<tr>
<td>P value</td>
<td>0.40</td>
<td>–</td>
</tr>
</tbody>
</table>

P value refers to the comparison between PIT-CS and ECT-CS.

Discussion

These ERCUSYN data show that the use of diagnostic tests for CS varies across European countries and partly differs from the currently available guidelines. Furthermore, late-night salivary cortisol (LSaC) assay is not frequently performed in the ERCUSYN participating centers despite being advocated as an easy and reliable tool to diagnose CS (24).

The most used measurement in the diagnostic work-up of CS is urinary free cortisol (UFC), which has been suggested as a first-line screening test in the current Endocrine Society guidelines (24). The other two recommended tests, the overnight 1mg DST and LSaC, were performed in 60 and 25% of ERCUSYN patients respectively. However the use of LSaC has increased over time among the ERCUSYN centers, indicating that this measurement is progressively being recognized as a useful diagnostic tool in suspected CS across Europe. LSaC has convincingly been proposed as a first-line diagnostic test in CS in 1998, and Endocrine Society guidelines endorsed its use in 2008 (24, 26). Our data reflect that a lapse of time is needed to introduce evidence-based recommendations into the daily clinical practice. In addition, it should be borne in mind that one-quarter of patients were diagnosed as having CS before 2008, when the Endocrine Society guidelines were published.

Recent studies showed that LSaC is a noninvasive, valid alternative to UFC for diagnosing CS in light of its simple collection procedure and elevated diagnostic performance (10, 27). In fact, LSaC accurately reflects the plasma free cortisol concentrations irrespective of the saliva production rate and corticosteroid-binding globulin (CBG) variability (12).

Loss of nighttime cortisol nadir in saliva is a hallmark of endogenous hypercortisolism, and reliably allows the identification of mild CS in those patients having normal or slightly elevated UFC (9, 16, 23, 27, 28). LSaC supported the diagnosis of CS in 88% of ERCUSYN patients with this measurement available, which was similar to the 93% observed for UFC (data not shown). Likewise, no
differences were reported in the diagnostic performance of LSaC and UFC within each etiologic group. Despite its good performance and practical advantages, measurement of LSaC is not as common as expected across Europe, likely due to misconcepted cost-effectiveness concerns and still limited access to the assay in some institutions (29). There is also some evidence that its performance is variable across centers (30). However several relatively inexpensive immunoassays are now commercially available, and have been proven to yield a good diagnostic performance (12, 31). On the other hand, the cost of liquid chromatography/tandem mass spectrometry (LC/TMS), which avoids the cross-reactivity between cortisol and synthetic steroids, is rapidly decreasing, making it a feasible option even for routine diagnostic laboratories (32). European authorities should make an effort to set up a program for quality assessment and harmonization of different LSaC assays, or promote the diffusion of a well-validated method, which can be easily adopted by all the reference laboratories (12, 32). Of note, groups entering more than 20 patients into ERCUSYN were more likely to include LSaC (or LSeC) assessment in the work-up of CS as compared with those entering less than 20 patients, suggesting that the clinical experience of a given center and/or the availability of adequate assays are the important factors impacting on the diagnostic choices.

Noteworthily, MSeC and ACTH were the most frequently reported tests in the ERCUSYN diagnosis section. MSeC is not advisable in the diagnostic work-up of CS due to its low reliability (33). Accordingly, MSeC supported the diagnosis in only half of 82% of ERCUSYN patients in whom it was performed (data not shown). It should be emphasized that a significant number of MSeC assays reported in the ERCUSYN were likely to be performed not as independent tests, but within different dynamic tests, such as diurnal cortisol rhythm assessment, LDDST and HDDST. Because the ERCUSYN database is not able to clarify in what context the MSeC measurement was performed, data on this test should be interpreted with caution.

Measurement of ACTH is useful in the differential diagnosis of CS (1). A single reported ACTH measurement in the ERCUSYN supported the diagnosis of PIT-CS and ECT-CS in 96 and 93% of patients respectively, which was similar to the 99% reported in ADR-CS. However recent evidence suggests that ACTH assessment may be misleading in CS, mainly depending on the assay used, in that up to 40% of patients with ACTH-independent CS might have normal corticotrophin values (34). Moreover, ACTH should be measured at least from two independent samples in order to avoid misinterpretation in ACTH-dependent CS, due to its episodic secretion (1) and because it requires stringent pre-analytic conditioning. We cannot exclude that some ERCUSYN centers chose to uniquely report a single ACTH value supporting the diagnosis among multiple samplings. Another limitation of the ERCUSYN is that it does not allow differentiating those tests, which have been performed in a given center to screen patients suspected of having hypercortisolism, from those used to confirm the diagnosis of CS. However most of the ERCUSYN participating centers are tertiary hospitals in their countries and, therefore they are more likely to admit patients referred from peripheral institutions to obtain the diagnostic confirmation of CS.

Despite these limitations, our data clearly showed a wide inter-country heterogeneity in local testing protocols for CS. When considering each of the most frequently performed tests, the use ranged broadly from around 10% to almost 100%, across the countries. This reflects the lack of a common European diagnostic strategy for this rare condition, which may partly be accounted for by logistic, economic, political and cultural differences. It would seem pertinent to attempt a more uniform approach throughout Europe for the patient with CS, aimed at maximizing the patient’s benefit on the one side, and considering cost rationalization on the other.

It should be acknowledged that missing or incomplete information is a potential shortcoming of a multicenter registry like the ERCUSYN, but the careful review for data quality control, which has been performed prior to data analysis, should have, in our opinion, attenuated the impact of this limitation on data reliability.

LSeC and 1 mg overnight DST were proven to support the diagnosis of both PIT-CS and ADR-CS more frequently than UFC, in line with previous reports. Invitti et al found that UFC levels fell within the normal range in 9% of PIT-CS and 15% of ADR-CS patients (33). It is well known that several technical issues might limit the reliability of the most common UFC immunoassays, including interference by metabolites and conjugates, inter-assay variability and intra-subject day-to-day variations (29). Of note, Rossi et al. did not report any difference in the UFC levels between patients with an adrenal mass and concomitant ‘subclinical’ hypercortisolism as compared with healthy controls (35). Although the diagnosis of a nonfunctioning adrenal incidentaloma was an exclusion criterion of ERCUSYN, we cannot rule out that some patients with subtle hypercortisolism associated with an adrenal incidentaloma were also included.
The usefulness of HDDST and CRH test for the differential diagnosis of ACTH-dependent CS is highly questionable due to their low accuracy (24). Accordingly, ERCUSYN data have shown that HDDST and CRH did not identify ECT-CS in 18 and 25% of patients respectively, who were subsequently found to have ectopic ACTH hypersecretion, supporting the recommendation that these tests should be performed only when IPSS is not feasible or available (1). Notably, a significant decrease in the use of CRH test (but not HDDST) has been observed over time in the ERCUSYN centers. This is likely due to the poor performance of this test and the limited availability of CRH in different countries, along with the continuous improvement of the imaging techniques, which more effectively support the differential diagnosis of hypercortisolism as compared with ‘traditional’ testing. This is also expected to significantly reduce the use of HDDST in the future.

It would seem, therefore, that while some of the tests recommended by the guidelines should be performed more frequently than has been done in recent years, others which still seem to be relied upon, should probably be avoided, given their limited practical utility.

Although not specifically mentioned in the current Endocrine Society guidelines, it is widely accepted that MRI is the first-choice imaging modality during the diagnostic process of ACTH-dependent hypercortisolemic states. The ERCUSYN data are compatible with these suggestions, since 89% of PIT-CS patients underwent pituitary MRI. In line with the previous reports, the diagnostic accuracy of MRI in the differential diagnosis of ACTH-dependent CS was not optimal, showing a sensitivity of 78% and a specificity of 89% (36, 37). In addition to this, a pituitary incidentaloma was found in 2% of patients who underwent an MRI, in whom an ACTH-secreting adenoma was subsequently ruled out as the cause of their hypercortisolism (38, 39). It should be emphasized that, while these ERCUSYN data refer to MRI equipment in use over the last 15 years, the rapid development of more sensitive devices might provide different results in the near future (40).

Of note, 22% of the PIT-CS patients had a normal pituitary MRI and, among those, two-thirds underwent IPSS, which confirmed a pituitary source of hypercortisolism in 95%. Overall, sensitivity and specificity of IPSS were 96 and 93% respectively, in accordance with the previous studies, which described a sensitivity ranging from 81 to 100% and a specificity from 90 to 95% (40). Thus, this invasive procedure appears to yield a better diagnostic accuracy than MRI and dynamic testing used for the differential diagnosis of ACTH-dependent CS. Therefore it should be considered a useful diagnostic tool to confirm a pituitary source of ACTH overproduction, mainly in those patients with sustained hypercortisolism having a negative MRI and/or inconclusive biochemical evaluation (36, 37, 39, 40, 41, 42, 43). Although the ERCUSYN results, obtained in the largest series published to date, suggest that IPSS is extensively used across Europe, it was not reported in some countries, indicating that its use should be further implemented, for instance, by supporting technical skills training and procedure supplies acquisition.

In conclusion, our data demonstrate that there is heterogeneity throughout Europe in the biochemical testing performed to detect hypercortisolism and diagnose CS. An effort should be taken in order to promote tests with better accuracy while limiting the use of those measurements, which are not recommended in the current guidelines. Notably, a change over time in the use of some tests has been observed. These results emphasize the importance of elaborating a common European strategy for the diagnosis and follow-up of CS, identifying the most accurate and cost-effective diagnostic approach to this rare disease, while taking into account specific inter-country differences.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-16-0967.

Declaration of interest
S M W received financial support, research grants and consultant or speaker fees from Ipsen, Novartis, Pfizer, HRA and Strongbridge. A T received financial support, research grants and consultant fees from Novartis and HRA Pharma. C J S has received lecture fees, consultancy remuneration or research support from HRA Pharma, Novartis and Strongbridge. T B received financial support, research grants and consultant or speaker fees from Ipsen, Novartis, Pfizer, Sandoz and Strongbridge. The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
ERCUSYN was set up with funding from the EU (PHP 800200) and been supported by unrestricted grants from Novartis, Ipsen, HRA and the European Society of Endocrinology.

Acknowledgements
ERCUSYN Study Group: A Ambrogio, Istituto Auxologico Italiano IRCCS, University of Milan, Italy; G Aranda, Department of Endocrinology, Hospital Clinic Barcelona, IDIBAPS, UB, Barcelona, Spain; M Arosio, Unit of Endocrine Diseases & Diabetology, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; M Balomenaki,
Differential diagnosis of Cushing's syndrome and pseudo-Cushing's states.


33 Invitti C, Pecori Giraldi F, De Martin M & Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Journal of Clinical Endocrinology and Metabolism 1999 84 440–448. (doi:10.1210/jcem.84.2.5465)


Clinical Study
E Valassi and others
Diagnostic tests in Cushing's syndrome


Received 24 November 2016
Revised version received 13 February 2017
Accepted 21 February 2017